These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35876221)

  • 1. Multivalent, Bispecific αB7-H3-αCD3 Chemically Self-Assembled Nanorings Direct Potent T Cell Responses against Medulloblastoma.
    Mews EA; Beckmann P; Patchava M; Wang Y; Largaespada DA; Wagner CR
    ACS Nano; 2022 Aug; 16(8):12185-12201. PubMed ID: 35876221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eradication of Established Tumors by Chemically Self-Assembled Nanoring Labeled T Cells.
    Petersburg JR; Shen J; Csizmar CM; Murphy KA; Spanier J; Gabrielse K; Griffith TS; Fife B; Wagner CR
    ACS Nano; 2018 Jul; 12(7):6563-6576. PubMed ID: 29792808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eradication of Heterogeneous Tumors by T Cells Targeted with Combination Bispecific Chemically Self-assembled Nanorings.
    Petersburg J; Vallera DA; Wagner CR
    Mol Cancer Ther; 2023 Mar; 22(3):371-380. PubMed ID: 36548194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
    Majzner RG; Theruvath JL; Nellan A; Heitzeneder S; Cui Y; Mount CW; Rietberg SP; Linde MH; Xu P; Rota C; Sotillo E; Labanieh L; Lee DW; Orentas RJ; Dimitrov DS; Zhu Z; Croix BS; Delaidelli A; Sekunova A; Bonvini E; Mitra SS; Quezado MM; Majeti R; Monje M; Sorensen PHB; Maris JM; Mackall CL
    Clin Cancer Res; 2019 Apr; 25(8):2560-2574. PubMed ID: 30655315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-EGFR Fibronectin Bispecific Chemically Self-Assembling Nanorings (CSANs) Induce Potent T Cell-Mediated Antitumor Responses and Downregulation of EGFR Signaling and PD-1/PD-L1 Expression.
    Kilic O; Matos de Souza MR; Almotlak AA; Wang Y; Siegfried JM; Distefano MD; Wagner CR
    J Med Chem; 2020 Sep; 63(18):10235-10245. PubMed ID: 32852209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bispecific T cell engager-armed T cells targeting integrin ανβ6 exhibit enhanced T cell redirection and antitumor activity in cholangiocarcinoma.
    Suwanchiwasiri K; Phanthaphol N; Somboonpatarakun C; Yuti P; Sujjitjoon J; Luangwattananun P; Maher J; Yenchitsomanus PT; Junking M
    Biomed Pharmacother; 2024 Jun; 175():116718. PubMed ID: 38744221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models.
    Warwas KM; Meyer M; Gonçalves M; Moldenhauer G; Bulbuc N; Knabe S; Luckner-Minden C; Ziegelmeier C; Heussel CP; Zörnig I; Jäger D; Momburg F
    Front Immunol; 2021; 12():719116. PubMed ID: 34484225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The making of multivalent gamma delta TCR anti-CD3 bispecific T cell engagers.
    van Diest E; Nicolasen MJT; Kramer L; Zheng J; Hernández-López P; Beringer DX; Kuball J
    Front Immunol; 2022; 13():1052090. PubMed ID: 36685546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemically self-assembled antibody nanorings (CSANs): design and characterization of an anti-CD3 IgM biomimetic.
    Li Q; So CR; Fegan A; Cody V; Sarikaya M; Vallera DA; Wagner CR
    J Am Chem Soc; 2010 Dec; 132(48):17247-57. PubMed ID: 21077608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pediatric medulloblastoma express immune checkpoint B7-H3.
    Li S; Poolen GC; van Vliet LC; Schipper JG; Broekhuizen R; Monnikhof M; Van Hecke W; Vermeulen JF; Bovenschen N
    Clin Transl Oncol; 2022 Jun; 24(6):1204-1208. PubMed ID: 34988920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Anti-B7-H3 × Anti-CD3 Bispecific Antibody with Potent Antitumor Activity.
    Feng Y; Xie K; Yin Y; Li B; Pi C; Xu X; Huang T; Zhang J; Wang B; Gu H; Fang J
    Life (Basel); 2022 Jan; 12(2):. PubMed ID: 35207448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors.
    Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A
    Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008
    [No Abstract]   [Full Text] [Related]  

  • 13. Engineering reversible cell-cell interactions using enzymatically lipidated chemically self-assembled nanorings.
    Wang Y; Kilic O; Csizmar CM; Ashok S; Hougland JL; Distefano MD; Wagner CR
    Chem Sci; 2020 Oct; 12(1):331-340. PubMed ID: 34168743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bispecific anti-CD3 x anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo.
    Ma J; Shang T; Ma P; Sun X; Zhao J; Sun X; Zhang M
    Invest New Drugs; 2019 Oct; 37(5):1036-1043. PubMed ID: 30706335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
    Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
    Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MEK Inhibitor Augments Antitumor Activity of B7-H3-Redirected Bispecific Antibody.
    Li H; Huang C; Zhang Z; Feng Y; Wang Z; Tang X; Zhong K; Hu Y; Guo G; Zhou L; Guo W; Xu J; Yang H; Tong A
    Front Oncol; 2020; 10():1527. PubMed ID: 32984002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting immunotherapy for bladder cancer using anti-CD3× B7-H3 bispecific antibody.
    Ma W; Ma J; Ma P; Lei T; Zhao M; Zhang M
    Cancer Med; 2018 Oct; 7(10):5167-5177. PubMed ID: 30253078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The bispecific B7H3xCD3 antibody CC-3 induces T cell immunity against bone and soft tissue sarcomas.
    Holzmayer SJ; Liebel K; Hagelstein I; Salih HR; Märklin M
    Front Immunol; 2024; 15():1391954. PubMed ID: 38765008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mRNA-based precision targeting of neoantigens and tumor-associated antigens in malignant brain tumors.
    Trivedi V; Yang C; Klippel K; Yegorov O; von Roemeling C; Hoang-Minh L; Fenton G; Ogando-Rivas E; Castillo P; Moore G; Long-James K; Dyson K; Doonan B; Flores C; Mitchell DA
    Genome Med; 2024 Jan; 16(1):17. PubMed ID: 38268001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting both GD2 and B7-H3 using bispecific antibody improves tumor selectivity for GD2-positive tumors.
    Rosenkrans ZT; Erbe AK; Clemons NB; Feils AS; Medina-Guevara Y; Jeffery JJ; Barnhart TE; Engle JW; Sondel PM; Hernandez R
    bioRxiv; 2024 May; ():. PubMed ID: 38853889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.